

AstraZeneca – Discontinuation of Lumoxiti[®] (moxetumomab pasudotox-tdfk)

 On January 10, 2023, <u>AstraZeneca announced</u> plans to permanently discontinue <u>Lumoxiti</u> (moxetumomab pasudotox-tdfk) from the U.S. market by August 31, 2023.

- The discontinuation was a business decision and was not due to safety or efficacy issues.

- Lumoxiti is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
- <u>Per AstraZeneca</u>, there has been very low clinical uptake of Lumoxiti since FDA approval in 2018 due to availability of other treatment options and possibly due to the specialized complexity of administration, toxicity prophylaxis and safety monitoring needs for patients.
- Healthcare providers should not initiate new treatment with Lumoxiti. Providers who are currently treating patients with Lumoxiti will have adequate time to complete six cycles of treatment.
- The potential impact of Lumoxiti withdrawal from the market on the care and outcomes of patients with HCL is expected to be mitigated by use of alternative existing therapies.
- Refer to AstraZeneca's <u>Dear Healthcare Provider Letter</u> for more information regarding alternative therapies.

Product Description	NDC#
Lumoxiti (moxetumomab pasudotox-tdfk) 1 mg lyophilized cake or powder in a single- dose vial	0310-4700-01



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.